MAPT and Brain atrophy: Improving our knowledge of how baseline measures of tau, neuroinflammation, and brain atrophy predict cognitive decline in Alzheimer’s disease may inform future cost-effectiveness of studies in large and epidemiologically representative cohorts of patients.